A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability

Nanomedicine

Volumn 11, Issue 14, 2016, Pages 1801-1816

  Chai, Fujuan ^a   Sun, Linlin ^b,c   Ding, Yafei ^d   Liu, Xiaoqing ^e   Zhang, Yajie ^a   Webster, Thomas J ^b,c,f   Zheng, Chunli ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c Northeastern University   (United States)

^d Jiangsu Hengrui Medicine Co Ltd   (China)

^e Zhoupu Hospital of Shanghai Pudong New District   (China)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

BCS class IIb drugs; bioavailability; enhanced dissolution; nanoemulsion; phase distribution; solid self nanoemulsifying drug delivery system

Indexed keywords

DABIGATRAN ETEXILATE; ANTITHROMBIN; DABIGATRAN; DRUG VEHICLE; EMULSION; EXCIPIENT; SURFACTANT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSIBLE TABLET; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; RAT; SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; EMULSION; ORAL DRUG ADMINISTRATION; PHASE TRANSITION; SOLUBILITY; SPRAGUE DAWLEY RAT; STROKE; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANIMALS; ANTITHROMBINS; BIOLOGICAL AVAILABILITY; DABIGATRAN; EMULSIONS; EXCIPIENTS; MALE; PARTICLE SIZE; PHARMACEUTICAL VEHICLES; PHASE TRANSITION; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STROKE; SURFACE-ACTIVE AGENTS; THROMBOEMBOLISM;

EID: 84978524250     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm-2016-0138     Document Type: Article

References (55)

1. Ebner T, Wagner K, Wienen W. Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab. Dispos. 38(9), 1567-1575 (2010
2. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36(2), 386-399 (2008
3. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921), 955-962 (2014
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. Engl. J. Med. 361(12), 1139-1151 (2009
5. Paikin JS, Haroun MJ, Eikelboom JW. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. Expert Rev. Cardiovasc. Ther. 9(3), 279-286 (2011
6. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591), 949-956 (2007
7. Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur. J. Pharm. Sci. 57, 152-163 (2014
8. Xu H. Profiling ester prodrug activation: an activity based protein profiling (ABPP) approach. University of Michigan, USA (2015
9. Brueck S, Paetz J, Koeberle M, Strohmeyer J. US 0052262 (2013
10. Kroselj V. WO 001156A2 (2012
11. Tang B, Cheng G, Gu JC, Xu CH. Development of solid selfemulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov. Today 13(13), 606-612 (2008
12. Mu H, Holm R, Mullertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm. 453(1), 215-24 (2013
13. Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Selfemulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov. Today 15(21), 958-965 (2010
14. Date AA, Desai N, Dixit R, Nagarsenker M. Selfnanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine 5(10), 1595-1616 (2010
15. Rao SVR, Shao J. Self-nanoemulsifying drug delivery system (SNEDDS) for oral delivery of protein drugs: I. Formulation development. Int. J. Pharm. 362(1), 2-9 (2008
16. Jyothi BJ, Sreelakshmi K. Design and evaluation of selfnanoemulsifying drug delivery system of flutamide. J. Young Pharm. 3(1), 4-8 (2011
17. Lei Y, Lu Y, Qi J, et al. Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility. Int. J. Nanomedicine 6, 795-805 (2011
18. Engelmann FM, Rocha SVO, Toma HE, Araki K, Baptista MS. Determination of n-octanol/water partition and membrane binding of cationic porphyrins. Int. J. Pharm. 329(1), 12-18 (2007
19. Bachynsky MO, Shah NH, Patel CI, Malick AW. Factors affecting the efficiency of a self-emulsifying oral delivery system. Drug Dev. Ind. Pharm. 23(8), 809-816 (1997
20. Wang L, Li CR, Jiang XH. In situ intestinal absorption behaviors of tanshinone IIA from its inclusion complex with hydroxypropyl-ß-cyclodextrin. Biol. Pharm. Bull. 30(10), 1918-1922 (2007
21. Sun M, Liu P, Fu XL, Xu WR, Tang LD. Determination of dabigatran in rat plasma by HPLC. Chin. J. New Drugs 10, 022 (2013
22. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb. Haemost. 83(5), 657-660 (2000
23. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism. J. Gen. Intern. Med. 21(7), 722-727 (2006
24. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics -2010 update A report from the American Heart Association. Circulation 121(7), e46-e215 (2010
25. Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world?s top oral drugs. AAPS J. 11(4), 740-746 (2009
26. Kim M, Kim J, Park HJ, Cho WK, Cha KH, Hwang SJ. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int. J. Nanomedicine 6, 2997-3009 (2011
27. Wang L, Dong J, Chen J, Eastoe J, Li X. Design and optimization of a new self-nanoemulsifying drug delivery system. J. Colloid Interf. Sci. 330(2), 443-448 (2009
28. Yoo JH, Shanmugam S, Thapa P, et al. Novel selfnanoemulsifying drug delivery system for enhanced solubility and dissolution of lutein. Arch. Pharm. Res. 33(3), 417-426 (2010
29. Hathout RM, Elshafeey AH. Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker. Eur. J. Pharm. Biopharm. 82(2), 230-240 (2012
30. Singh AK, Chaurasiya A, Awasthi A, et al. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS). AAPS PharmSciTech 10(3), 906-916 (2009
31. Kommuru TR, Gurley B, Khan MA, Reddy IK. Selfemulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int. J. Pharm. 212(2), 233-246 (2001
32. Elnaggar YS, El-Massik MA, Abdallah OY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int. J. Pharm. 380(1), 133-141 (2009
33. Balakrishnan P, Lee BJ, Oh DH, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid selfemulsifying drug delivery system (SEDDS). Eur. J. Pharm. Biopharm. 72(3), 539-545 (2009
34. Xi J, Chang Q, Chan CK, et al. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS PharmSciTech. 10(1), 172-182 (2009
35. Swenson ES, Milisen WB, Curatolo W. Intestinal permeability enhancement: efficacy, acute local toxicity, and reversibility. Pharm. Res. 11(8), 1132-1142 (1994
36. Li P, Ghosh A, Wagner RF, Krill S, Joshi YM, Serajuddin AT. Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. Int. J. Pharm. 288(1), 27-34 (2005
37. Khoo SM, Humberstone AJ, Porter CJ, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharm. 167(1), 155-164 (1998
38. Gursoy N, Garrigue JS, Razafindratsita A, Lambert G, Benita S. Excipient effects on in vitro cytotoxicity of a novel paclitaxel self-emulsifying drug delivery system. J. Pharm. Sci. 92(12), 2411-2418 (2003
39. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. 45(1), 89-121 (2000
40. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 62(11), 1637-1645 (2010
41. Calzolai L, Gilliland D, Garcìa CP, Rossi F. Separation and characterization of gold nanoparticle mixtures by flow-fieldflow fractionation. J. Chromatogr. A 1218(27), 4234-4239 (2011
42. Craig DQM, Barker SA, Banning D, Booth SW. An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int. J. Pharm. 114(1), 103-110 (1995
43. Dixit RP, Nagarsenker MS. Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Eur. J. Pharm. Sci. 35(3), 183-192 (2008
44. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50(1), 3-12 (2000
45. Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir. Eur. J. Pharm. Biopharm. 79(2), 349-356 (2011
46. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. 45(5), 555-565 (2005
47. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47(1), 47-59 (2008
48. Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2(4), 289-295 (2003
49. Seo YG, Kim DH, Ramasamy T, et al. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int. J. Pharm. 452(1), 412-420 (2013
50. Araya H, Tomita M, Hayashi M. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion III: the permeation mechanism of a poorly water soluble drug entrapped O/W microemulsion in rat isolated intestinal membrane by the using chamber method. Drug Metab. Pharm. 21(1), 45-53 (2006
51. Wei L, Sun P, Nie S, Pan W. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev. Ind. Pharm. 31(8), 785-794 (2005
52. Gershanik T, Haltner E, Lehr CM, Benita S. Chargedependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. Int. J. Pharm. 211(1), 29-36 (2000
53. Jing B, Wang Z, Yang R, et al. Enhanced oral bioavailability of felodipine by novel solid self-microemulsifying tablets. Drug Dev. Ind. Pharm. 1-7 (2015
54. Xiao L, Yi T, Liu Y. A new self-microemulsifying mouth dissolving film to improve the oral bioavailability of poorly water soluble drugs. Drug Dev. Ind. Pharm. 39(9), 1284-1290 (2013
55. Qi X, Qin J, Ma N, Chou X, Wu Z. Solid selfmicroemulsifying dispersible tablets of celastrol: formulation development, characterization and bioavailability evaluation. Int. J. Pharm. 472(1), 40-47 (2014